- Home
- CADL vs ESPR Comparison
CADL vs ESPR Comparison
Compare CADL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | ESPR |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 898.5M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CADL | ESPR |
|---|---|---|
| Price | $5.45 | $3.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $19.43 | $6.67 |
| AVG Volume (30 Days) | 943.3K | ★ 4.9M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $4.25 | $0.69 |
| 52 Week High | $13.68 | $4.13 |
Technical Indicators
Market Signals| Indicator | CADL | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 49.95 |
| Support Level | $5.45 | $3.87 |
| Resistance Level | $6.14 | $4.05 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 7.88 | 11.00 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.